Journal article

Quantifying the direct public health care cost of systemic sclerosis A comprehensive data linkage study

Kathleen Morrisroe, Wendy Stevens, Joanne Sahhar, Gene-Siew Ngian, Candice Rabusa, Nava Ferdowsi, Catherine Hill, Susanna Proudman, Mandana Nikpour

MEDICINE | LIPPINCOTT WILLIAMS & WILKINS | Published : 2017

Abstract

To quantify the direct healthcare cost of systemic sclerosis (SSc) and identify its determinants. Healthcare use was captured through data linkage, wherein clinical and medication data for SSc patients from the state of Victoria enrolled in the Australian Scleroderma Cohort Study were linked with the Victorian hospital admissions and emergency presentations data sets, and the Medicare Benefits Schedule which contains all government subsidized ambulatory care services, for the period 2011-2015. Medication cost was determined from the Pharmaceutical Benefits Scheme. Costs were extrapolated to all Australian SSc patients based on SSc prevalence of 21.1 per 100,000 and an Australian population o..

View full abstract

Grants

Awarded by National Health and Medical Research Council of Australia Career Development Fellowship


Awarded by National Health and Medical Research Council of Australia Postgraduate Scholarship


Funding Acknowledgements

This work was supported by Scleroderma Australia, Arthritis Australia, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia and Pfizer. MN holds a National Health and Medical Research Council of Australia Career Development Fellowship (APP 1126370). KM holds National Health and Medical Research Council of Australia Postgraduate Scholarship (APP1113954).